{
    "ticker": "BCYC",
    "name": "Bicycle Therapeutics plc",
    "description": "Bicycle Therapeutics plc is a biotechnology company focused on pioneering a new class of therapeutics based on its proprietary bicyclic peptide platform. Founded in 2009 and headquartered in Cambridge, UK, Bicycle is dedicated to transforming the treatment landscape for cancer and other serious diseases by harnessing the unique properties of bicyclic peptides, which are small, stable, and highly selective molecules. The company's innovative approach allows for the development of targeted therapies that can effectively bind to disease targets, leading to improved efficacy and safety profiles compared to traditional therapies. Bicycle Therapeutics is advancing a pipeline of product candidates, including BT5528, a bicyclic peptide-drug conjugate for the treatment of cancer, and BT8009, an immuno-oncology candidate. The company collaborates with leading pharmaceutical companies to further its research and development efforts, aiming to bring transformative medicines to patients with unmet medical needs. With a vision to unlock the potential of bicyclic peptides, Bicycle Therapeutics is positioning itself as a leader in the biotechnology field, focusing on precision medicine and innovative therapeutic solutions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, UK",
    "founded": "2009",
    "website": "https://www.bicycletherapeutics.com",
    "ceo": "Kevin Lee",
    "social_media": {
        "twitter": "https://twitter.com/BicycleTx",
        "linkedin": "https://www.linkedin.com/company/bicycle-therapeutics/"
    },
    "investor_relations": "https://investors.bicycletherapeutics.com",
    "key_executives": [
        {
            "name": "Kevin Lee",
            "position": "CEO"
        },
        {
            "name": "James Noble",
            "position": "Chairman"
        },
        {
            "name": "Steven M. Dyer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "BT5528",
                "BT8009"
            ]
        }
    ],
    "seo": {
        "meta_title": "Bicycle Therapeutics plc | Innovative Biotechnology Solutions",
        "meta_description": "Explore Bicycle Therapeutics plc, a leader in biotechnology focused on developing a new class of targeted therapeutics using bicyclic peptides. Discover the company's innovative pipeline and commitment to transforming treatment for cancer and serious diseases.",
        "keywords": [
            "Bicycle Therapeutics",
            "Biotechnology",
            "Bicyclic Peptides",
            "Cancer Therapies",
            "Precision Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is Bicycle Therapeutics known for?",
            "answer": "Bicycle Therapeutics is known for its innovative biotechnology platform that develops therapeutics based on bicyclic peptides."
        },
        {
            "question": "Who is the CEO of Bicycle Therapeutics?",
            "answer": "Kevin Lee is the CEO of Bicycle Therapeutics plc."
        },
        {
            "question": "Where is Bicycle Therapeutics headquartered?",
            "answer": "Bicycle Therapeutics is headquartered in Cambridge, UK."
        },
        {
            "question": "What are Bicycle Therapeutics' main products?",
            "answer": "Bicycle Therapeutics' main products include BT5528 and BT8009, both aimed at treating cancer."
        },
        {
            "question": "When was Bicycle Therapeutics founded?",
            "answer": "Bicycle Therapeutics was founded in 2009."
        }
    ],
    "competitors": [
        "BMY",
        "AMGN",
        "GILD"
    ],
    "related_stocks": [
        "NVAX",
        "MRNA",
        "REGN",
        "VRTX"
    ]
}